Bone mass and long-term monophasic oral contraceptive treatment in young women

Franco Polatti; Francesca Perotti; Nadia Filippa; Davide Gallina; Rossella E. Nappi

doi:10.1016/0010-7824(95)00036-A

Bone mass and long-term monophasic oral contraceptive treatment in young women

Franco Polatti, Francesca Perotti, Nadia Filippa, Davide Gallina, Rossella E. Nappi

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article

Abstract

A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p

Original language	English
Pages (from-to)	221-224
Number of pages	4
Journal	Contraception
Volume	51
Issue number	4
DOIs	https://doi.org/10.1016/0010-7824(95)00036-A
Publication status	Published - 1995

Fingerprint

Keywords

alkaline phosphatase
bone mass density
monophasic contraceptive
urinary excretion

ASJC Scopus subject areas

Obstetrics and Gynaecology
Reproductive Medicine
Medicine(all)

Cite this

Polatti, F., Perotti, F., Filippa, N., Gallina, D., & Nappi, R. E. (1995). Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception, 51(4), 221-224. https://doi.org/10.1016/0010-7824(95)00036-A

@article{9f793f85897c4b8d9f5655a8dca28fea,

title = "Bone mass and long-term monophasic oral contraceptive treatment in young women",

abstract = "A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p ",

keywords = "alkaline phosphatase, bone mass density, monophasic contraceptive, urinary excretion",

author = "Franco Polatti and Francesca Perotti and Nadia Filippa and Davide Gallina and Nappi, {Rossella E.}",

year = "1995",

doi = "10.1016/0010-7824(95)00036-A",

language = "English",

volume = "51",

pages = "221--224",

journal = "Contraception",

issn = "0010-7824",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Bone mass and long-term monophasic oral contraceptive treatment in young women

AU - Polatti, Franco

AU - Perotti, Francesca

AU - Filippa, Nadia

AU - Gallina, Davide

AU - Nappi, Rossella E.

PY - 1995

Y1 - 1995

N2 - A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p

AB - A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p

KW - alkaline phosphatase

KW - bone mass density

KW - monophasic contraceptive

KW - urinary excretion

UR - http://www.scopus.com/inward/record.url?scp=0028916930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028916930&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(95)00036-A

DO - 10.1016/0010-7824(95)00036-A

M3 - Article

C2 - 7796586

AN - SCOPUS:0028916930

VL - 51

SP - 221

EP - 224

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -

Access to Document

10.1016/0010-7824(95)00036-A